_256_384.jpg)
Cipla's Lanreotide Injection is AP-rated therapeutic equivalent generic version of Somatuline Depot (Lanreotide) Injection
Achira is engaged in development and commercialization of PoC medical test kits in India
Sanofi India has reported total income of Rs. 738.9 crores during the period ended March 31, 2024
The company has posted net profit of Rs. 4,121.55 crores for the Financial Year ended March 31, 2024
CHL is strengthening its play in the fast-growing beauty and personal care sector
Cipla will be responsible for the distribution of Sanofi India's six CNS brands including Frisium
Mungara has over 25+ years of experience in the supply chain domain
Cipla completes transfer of Generics Business Undertaking
Cipla has reported total income of Rs. 6,788.44 crores during the period ended December 31, 2023
The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions
Subscribe To Our Newsletter & Stay Updated
